Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | TGM2 | P21980 | 4/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.33 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10000909 | 0.85 | ALDH1A1 (0.36) | TSHRALDH1A1MAPK1TDP1TGM2 | |
| SCHEMBL14129244 | 0.83 | ALDH1A1 (0.39) | TSHRALDH1A1MAPK1TDP1TGM2 | |
| SCHEMBL905081 | 0.80 | ZDHHC20 (0.44) | TSHRALDH1A1MAPK1TDP1TGM2 | |
| SCHEMBL15159370 | 0.79 | CNR2 (0.36) | — | |
| SCHEMBL15132327 | 0.79 | ZDHHC20 (0.46) | TSHRALDH1A1MAPK1TDP1TGM2 | |
| SCHEMBL28384050 | 0.77 | TSHR (0.48) | TSHRALDH1A1MAPK1TDP1TGM2 | |
| SCHEMBL15132328 | 0.76 | TSHR (0.46) | TSHRALDH1A1MAPK1TDP1TGM2 | |
| SCHEMBL905121 | 0.74 | TGFBR1 (0.36) | TDP1 | |
| SCHEMBL15159382 | 0.73 | TSHR (0.35) | TSHRTGM2 | |
| SCHEMBL905099 | 0.73 | ALDH1A1 (0.41) | TSHRALDH1A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9204652-B2 | Antibacterial agent, substrate surface treatment method using the same, antibacterial agent composition, and substrate surface treatment method using the same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20130189220-A1 | Antibacterial Agent, Substrate Surface Treatment Method Using The Same, Antibacterial Agent Composition, And Substrate Surface Treatment Method Using The Same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2013-07-25 | — | — | US | disclosed |
| WO-2012043619-A1 | ANTIBACTERIAL AGENT, SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME, ANTIBACTERIAL AGENT COMPOSITION, AND SUBSTRATE SURFACE TREATMENT METHOD USING THE SAME | セントラル硝子株式会社 (JP) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189220-A1 | Antibacterial Agent, Substrate Surface Treatment Method Using The Same, Antibacterial Agent Composition, And Substrate Surface Treatment Method Using The Same | SEM1, CD81, VMA21 | TSHR 3910/4885ALDH1A1 1200/4885MAPK1 1590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.